Alembic Pharmaceuticals Ltd Q2 FY2024 Concall Summary

Key Takeaways

• Steady quarter, no fireworks: Revenue grew 8% YoY to ₹1,595 crores, with US and animal health leading while India lagged the market. Management stayed characteristically guarded on forward guidance.
• New facility costs are now structural: ₹60–70 crores per quarter in cash expenses from F2, F3, F4 units are the new baseline, a permanent reset to the cost base that was previously capitalized.
• India business hit an air pocket: 5% growth trailed the 7% industry rate, dragged by a weak acute season, but specialty therapies held up at 9% and management expects a strong double-digit rebound in H2.
• US business is a slow build, not a breakout: 6% YoY growth with 14% sequential lift came from new launches and some base improvement, but pricing erosion persists and management won't chase share by dropping prices.
• What to watch next quarter: Whether India's acute segment stabilizes as promised, the pace of the 10+ planned US launches in H2, and any margin relief now that the solar plant is operational.

India Business: A Weak Acute Season, Specialty Holding Up

• Acute drag, specialty offset: Antibiotic and respiratory segments saw heavy market degrowth, though Alembic's relative performance was better than the market. Specialty therapies (gynecology, antidiabetic, ophthalmology) grew an impressive 9%.
• High base effect at play: Last year's post-COVID demand for azithromycin and liquid preparations created a tough comparable, so net debt growth of +3.5% to +4% vs market still reflects underlying resilience.
• H2 recovery bet: Strong new launches are lined up across key product segments for H2, and management expects the acute piece to normalize in Q3/Q4, returning India to high single-digit to double-digit growth.

Shaunak Amin: "We expect the market to stabilize coming into Q3, Q4. And we expect growth to return to a strong double digit growth. Having that said, if market throws no surprises in the future, we should be very comfortable."

US Business: Gradual Ramp, Pricing Discipline

• Sequential lift from launches: US business grew 14% QoQ, driven by new product launches from the new facilities plus some improvement in the base business. Volume demand remains strong.
• Pricing erosion is structural: Erosion continues molecule-by-molecule, with some competitors more aggressive than others. Management explicitly refuses to drop prices to buy market share, calling the trade-off unacceptable.
• Portfolio broadening underway: The company has moved from 100% oral solids to a mix that now includes ~15 ophthalmic products, derm products, 2 inhalation products, and injectables coming through from F3.
• Derm benefited from shortages: The derm portfolio performed well in H1 predominantly due to market shortages, which helped profitability, but pricing challenges persist and the shortage tailwind may not be durable.
• Inflection is a wait-and-see story: Management declined to call a timeline for material change from the current run rate, asking for a couple of quarters to watch how the 10+ planned H2 launches perform.

Pranav Amin: "It's not as simple as branded market, right? And the reason what we do is to pick market shares, really you have to go and drop prices and we won't be comfortable with dropping prices in most of these products."

New Facilities: The Cost Reset

• Structural step-up in opex: ₹61 crores in Q1 and ₹116 crores in H1 of cash expenses, plus ₹12 crores (Q2) and ₹23 crores (H1) of depreciation for F2, F3, F4 units were expensed this year versus capitalized in the prior corresponding period, making EBITDA and net profit not exactly comparable YoY.
• New quarterly baseline: Other expenses now carry an additional ₹60–70 crores per quarter from the new facilities, and management confirmed this is the new base going forward.
• Early launches from new assets: From F3 (general injectable facility), the company launched one ophthalmic and one injectable product; on the oncology side, a couple of products launched with good pickup. Management cautioned it is still early days and wants a couple more quarters before drawing conclusions.

Pranav Amin: "So if you see the new facilities, yes, this is the new base, because you have about Rs. 60 crores, Rs. 70 crores of cost for the new facilities, so this will be the new base."

Animal Health & Ex-US: Quiet Outperformers

• Animal health grew 32%: A new livestock division with 350 headcount has been added, and management expects growth to accelerate further in coming quarters and years.
• Ex-US formulations up 17%: This vertical and API (up 10%) have been performing very well over the last couple of years, and management expressed confidence in both sustaining good performance through the current year.

Margins & Cost Structure

• Gross margin stable, not expanding: Gross margin has been consistent and slightly better than the previous year, with minor sequential changes attributable to product mix. Management reiterated a past aspirational target of 70% but gave no timeline.
• R&D optimization on track: R&D spend was ₹121 crores (8% of sales), and cost optimization efforts are progressing. The ANDA filing rate will reduce from 20–25 per year to about 15, with a shift toward more complex filings on the injectable side.
• Solar plant now live: A 12 MW solar plant was commissioned on 4 October 2023 and is operating at rated capacity, with an 18–20% ROI and sub-5-year payback. Capitalization and energy savings will flow from Q3 onwards.
• No margin guidance: Management declined to provide ballpark guidance on either gross margin or EBITDA margin, stating only that they are happy to continue at the current EBITDA number for now.

R&D Pipeline & Portfolio Evolution

• Filing pace moderating, complexity rising: Cumulative ANDA filings stand at 252 (2 filed in Q2), with 190 approvals including 25 tentative approvals. The company aims to get more complex filings, particularly on the injectable side.
• Portfolio diversification in motion: The US portfolio now spans 129 products across oral solids, ophthalmics, derm, inhalation, and injectables. Three products were launched in the US during Q2, with over 10 more planned in H2.
• Injectable ramp is nascent: Management declined to form an opinion on the injectable opportunity based on only a few products, asking for a couple of quarters before assessing trajectory.

Pranav Amin: "It's still early days for us... For me to give a better answer, I would still require a couple of quarters because these are just very few products. I don't want to have an opinion just based on a few products."

Guidance & Commitments

Key Metrics